GlassScriptPhysician profile
Ana Petrova
NPI 1164843926
$1,038.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $186.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.35 | 2019-2020 | |
| Janssen Biotech, INC. | $66.23 | 2019 | |
| Vifor Pharma, INC. | $42.97 | 2019 | |
| Akebia Therapeutics INC | $29.67 | 2019 | |
| Shire North American Group INC | $28.20 | 2019 | |
| Dova Pharmaceuticals | $28.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.29 | 2020 | |
| Gilead Sciences, INC. | $22.54 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $18.76 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.16 | 2019 | |
| Daiichi Sankyo INC. | $11.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Petrova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.